Asegua Therapeutics
Asegua Therapeutics LLC, a 2018-founded Gilead Sciences affiliate based in Foster City, CA, distributes US authorized generic versions of EPCLUSA and HARVONI for Hepatitis C through authorized wholesalers, supported by the Support Path patient assistance program.
- Company typePrivate
- Founded2018
- HeadquartersFoster City, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Asegua Therapeutics does
Asegua Therapeutics LLC is a Foster City, California-based pharmaceutical company founded in 2018 as a wholly-controlled affiliate of Gilead Sciences Inc. The company commercializes authorized generic versions of two of Gilead's Hepatitis C treatments: sofosbuvir/velpatasvir (authorized generic of EPCLUSA, 400/100 mg) and ledipasvir/sofosbuvir (authorized generic of HARVONI, 90/400 mg), both supplied as 28-count blister packs. Asegua does not develop proprietary technology or novel molecules; its competitive position derives from its licensing relationship with Gilead and the regulatory pathway available to authorized generics.
The company's business model is a one-time pharmaceutical product sale distributed exclusively through a network of authorized distributors of record, anchored by AmerisourceBergen, Cardinal Health, and McKesson and supplemented by ten regional wholesalers. Asegua does not sell directly to pharmacies or patients. Its customer segments are Hepatitis C patients (end users) and the healthcare providers who prescribe the regimens, with a layered patient services offering — the Support Path program — providing benefits investigation, co-pay coupons, prior authorization support, and nurse hotline referrals, alongside dedicated product support phone lines for each authorized generic. Pricing is not publicly disclosed and is shaped by payer and pharmacy benefit manager negotiations.
The company operates as a US-only distributor within Gilead's corporate structure, with no independent funding, no public listing, and no disclosed leadership team beyond its corporate affiliation. Asegua's scope is defined by its two-product portfolio and its channel relationships, with all trademarks (EPCLUSA, HARVONI, SUPPORT PATH) held by Gilead and used by Asegua under license. The company functions as a controlled access vehicle rather than an independently scaled enterprise.
Asegua Therapeutics firmographics
Firmographics- Name
- Asegua Therapeutics
- Legal name
- Asegua Therapeutics LLC
- Website
- https://asegua.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Asegua Therapeutics LLC, a 2018-founded Gilead Sciences affiliate based in Foster City, CA, distributes US authorized generic versions of EPCLUSA and HARVONI for Hepatitis C through authorized wholesalers, supported by the Support Path patient assistance program.
- Ownership category
- akta.pro rank
Asegua Therapeutics industry classification
Industry- Product category
- Generic Hepatitis C Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)
Keywords
Where Asegua Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Foster City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Asegua Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Marketing or Sales, Personnel, Others
Revenue model
- Pharmaceutical Product Sales: Asegua Therapeutics generates revenue through the sale of authorized generic Hepatitis C medications (sofosbuvir/velpatasvir and ledipasvir/sofosbuvir) distributed through authorized pharmaceutical wholesalers to pharmacies and healthcare providers.
Go-to-market motion2 records
Distribution channels12 records
Marketing channels3 records
Asegua Therapeutics product offering
Product offeringCore offering
Asegua Therapeutics LLC manufactures and distributes authorized generic versions of two Gilead Sciences Hepatitis C therapies in the United States: an authorized generic of EPCLUSA (sofosbuvir/velpatasvir 400/100 mg) and an authorized generic of HARVONI (ledipasvir/sofosbuvir 90/400 mg), both packaged in 28-count blister packs. The company sells these drugs exclusively through authorized pharmaceutical wholesale distributors and supports patient access via the Support Path program, which provides benefits investigation, co-pay coupons, prior authorization support, and nurse hotline referrals.
Product overview
Asegua Therapeutics LLC operates as a pharmaceutical company offering authorized generic versions of brand-name hepatitis C medications. The company provides two distinct drug products: an authorized generic of EPCLUSA (sofosbuvir/velpatasvir) and an authorized generic of HARVONI (ledipasvir/sofosbuvir). These medications are distributed through authorized distributors and supported by patient assistance programs including Support Path.
Differentiator
Problem solved
Functional benefit
Products and services
- Authorized Generic of EPCLUSA (sofosbuvir/velpatasvir) 400/100 mg tablets, 28-count blister pack (NDC 72626-2701-1) Authorized generic version of Gilead's EPCLUSA (sofosbuvir/velpatasvir) Hepatitis C direct-acting antiviral regimen, supplied as 400/100 mg tablets in a 28-count blister pack (NDC 72626-2701-1) to US pharmacies via authorized wholesale distributors and dispensed to patients with chronic Hepatitis C virus infection.
- Authorized Generic of HARVONI (ledipasvir/sofosbuvir) 90/400 mg tablets, 28-count blister pack (NDC 72626-2601-1) Authorized generic version of Gilead's HARVONI (ledipasvir/sofosbuvir) Hepatitis C direct-acting antiviral regimen, supplied as 90/400 mg tablets in a 28-count blister pack (NDC 72626-2601-1) to US pharmacies via authorized wholesale distributors and dispensed to patients with chronic Hepatitis C virus infection.
Companies that use Asegua Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Asegua Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Asegua Therapeutics partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, major and minor.
- Gilead Sciences Inc.coreAsegua Therapeutics LLC is an affiliate of Gilead Sciences Inc. The company was founded in 2018 and launched authorized generics of EPCLUSA (sofosbuvir/velpatasvir) and HARVONI (ledipasvir/sofosbuvir) under license from Gilead. This is a parent-subsidiary affiliation relationship.
- AmerisourceBergen CorporationmajorMajor pharmaceutical wholesale distributor authorized to distribute Asegua Therapeutics' authorized generic Hepatitis C medications (sofosbuvir/velpatasvir and ledipasvir/sofosbuvir) to pharmacies across the United States.
- Cardinal HealthmajorPharmaceutical distribution services company and authorized distributor of record for Asegua Therapeutics' authorized generic Hepatitis C medications.
- McKesson CorporationmajorMajor pharmaceutical wholesale distributor and authorized distributor of record for Asegua Therapeutics' authorized generic Hepatitis C medications.
- Capital Wholesale DrugminorRegional pharmaceutical wholesale distributor authorized to distribute Asegua Therapeutics' products.
- Dakota DrugminorRegional pharmaceutical wholesale distributor serving the upper Midwest, authorized to distribute Asegua Therapeutics' products.
- Morris & Dickson Co., Ltd.minorIndependent pharmaceutical wholesale distributor authorized to distribute Asegua Therapeutics' products.
- N.C. Mutual Wholesale Drug Co.minorRegional pharmaceutical wholesale distributor authorized to distribute Asegua Therapeutics' products.
- R&S Northeast/Dixon-ShaneminorRegional pharmaceutical wholesale distributor serving the Northeast, authorized to distribute Asegua Therapeutics' products.
- Smith Drug CompanyminorRegional pharmaceutical wholesale distributor authorized to distribute Asegua Therapeutics' products.
- Value Drug CompanyminorRegional pharmaceutical wholesale distributor authorized to distribute Asegua Therapeutics' products.
- H.D. SmithminorRegional pharmaceutical wholesale distributor authorized to distribute Asegua Therapeutics' products.
- Rochester Drug CooperativeminorRegional pharmaceutical wholesale distributor authorized to distribute Asegua Therapeutics' products.
Scale indicators1 record
Recent moves4 records
Expansion highlights2 records
Asegua Therapeutics competitors and assessment
Company assessmentDirect peers
- Aurobindo Pharma: A leading global generic pharmaceutical manufacturer with US Hep C antiviral product exposure. Aurobindo competes in the same authorized/ANDA generic antiviral category as Asegua and serves the same pharmacy and wholesaler channels.
- Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a broad US generic portfolio including antivirals. Teva operates the same authorized-distributor/wholesale model for generic prescription drugs and competes for the same Hep C prescription volume.
- Viatris: Major US-focused generic pharmaceutical company (formed from Mylan-Upjohn merger) with established antiviral and Hep C generic product lines. Viatris sells through the same Big 3 wholesaler channels and competes in the same payer/prescriber market.
- Sandoz: Novartis's generics division with a leading US generic injectables and orals portfolio including antivirals. Sandoz operates an analogous authorized-distributor model for generic prescription drugs distributed through AmerisourceBergen, Cardinal Health, and McKesson.
- Apotex: Large Canadian-headquartered generic pharmaceutical manufacturer with significant US generic presence, including antiviral products. Apotex competes for the same authorized-distributor slots and Hep C prescription share in the US market.
- Dr. Reddy's Laboratories: India-based global generic manufacturer with a US generics business covering antivirals. Dr. Reddy's distributes through the same major US wholesalers and competes in the same Hep C and adjacent antiviral generic categories.
- Zydus Lifesciences: India-based generic pharmaceutical company with US FDA-approved antiviral products including Hep C regimens. Zydus operates the same US-authorized-distributor commercial model targeting the same pharmacy/wholesaler customer base.
- Cipla: Major India-based generic pharmaceutical company with established US generic antiviral portfolio, including Hep C treatments. Cipla is a direct competitor in the generic antiviral space and uses an analogous wholesaler-distribution model in the US.
Broad incumbents
- AbbVie: Markets Mavyret, a competing pan-genotype Hepatitis C regimen, and operates broadly in the same therapeutic space. AbbVie's branded Mavyret is the primary clinical competitor to Asegua's authorized generics of EPCLUSA and HARVONI in the US Hep C market.
- Merck & Co. Marketed Zepatier, another once-daily Hepatitis C antiviral, and operates broadly in the US infectious-disease therapeutics market. Merck represents a larger incumbent competitor in the same Hep C therapeutic category that Asegua serves with authorized generics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Asegua Therapeutics social profiles
Digital presenceAsegua Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Asegua Therapeutics leadership team
Management profileNumber of profiles
Asegua Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Asegua Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Asegua Therapeutics
What does Asegua Therapeutics do?
Asegua Therapeutics LLC manufactures and distributes authorized generic versions of two Gilead Sciences Hepatitis C therapies in the United States: an authorized generic of EPCLUSA (sofosbuvir/velpatasvir 400/100 mg) and an authorized generic of HARVONI (ledipasvir/sofosbuvir 90/400 mg), both packaged in 28-count blister packs. The company sells these drugs exclusively through authorized pharmaceutical wholesale distributors and supports patient access via the Support Path program, which provides benefits investigation, co-pay coupons, prior authorization support, and nurse hotline referrals.
Is Asegua Therapeutics a public or private company?
Asegua Therapeutics is a private company. It is classified as corporate owned and is currently operating.
When was Asegua Therapeutics founded?
Asegua Therapeutics was founded in 2018. It employs 51 to 100 people.
Where is Asegua Therapeutics based?
Asegua Therapeutics is headquartered in Foster City, United States, in the North America region.
How does Asegua Therapeutics make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Asegua Therapeutics's main competitors?
Direct peers on record are Aurobindo Pharma, Teva Pharmaceutical Industries, Viatris, Sandoz, Apotex, Dr. Reddy's Laboratories, Zydus Lifesciences and Cipla. Broad incumbents are AbbVie and Merck & Co..
Does Asegua Therapeutics have an API?
No public API is recorded for Asegua Therapeutics.
What industry is Asegua Therapeutics in?
Asegua Therapeutics's product category is Generic Hepatitis C Pharmaceuticals. Its primary akta.pro industry code is HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 5122.